BEONE MEDICINES (06160) expects strong growth in performance in 2025, with adjusted net profit of approximately 918 million US dollars, turning losses into profits year-on-year.

BEONE MEDICINES (06160) announced that in the fourth quarter of 2025, global total revenue reached $1.5 billion, a year-on-year increase of 33%; total global revenue for the full year reached $5.3 billion, a year-on-year increase of 40%. Adjusted net profit for the fourth quarter of 2025 was approximately $225 million, a year-on-year increase of 12.97 times; full-year adjusted net profit was approximately $918 million, turning losses into profits year-on-year. Free cash flow in the fourth quarter of 2025 was $380 million, an increase of $397 million compared to the same period last year. For the full year of 2025, free cash flow was $942 million, an increase of $1.6 billion compared to the same period last year. The total revenue guidance for the full year of 2026 is expected to be between $6.2 billion and $6.4 billion. Of this, sales of Baiyueze (Zebutinib) in the fourth quarter reached $1.1 billion, a year-on-year increase of 38%; annual global sales reached $3.9 billion, a year-on-year increase of 49%. Baizean (Teralizumab) had global sales of $182 million in the fourth quarter of 2025, an increase of 18% year-on-year; full-year global sales reached $737 million, a year-on-year increase of 19%. "The strong financial performance achieved in the fourth quarter and full year of 2025 demonstrates our continued evolution as a global leader in the field of cancer treatment. The enduring competitive advantage we have built in clinical development and production, as well as our industry-leading and highly differentiated research pipeline, have laid a solid foundation for this achievement," said Mr. Ouleiqiang, co-founder, chairman, and CEO of BEONE MEDICINES. "Baiyueze has solidified its position as the global leader in the BTK inhibitor field. Its extensive regulatory approvals, deepening global presence, high recognition from clinical doctors, and unbeatable long-term efficacy and safety data in chronic lymphocytic leukemia (CLL) have collectively established a significant competitive advantage. At the same time, we are continuously expanding the indications and reimbursement coverage of Baizean in major global markets. With several key blood cancer products in late-stage clinical development nearing commercialization, and the continued release of encouraging data from our strong solid tumor pipeline, we will remain steadfast, further expand our leadership advantage, and move towards sustainable global growth in the next stage."